Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XPH Guru Trades in

XPH Guru Trades in

Q4 2014

XPH Guru Trades in Q4 2014

Ken Fisher 3,425 sh (New)
» More
Q1 2015

XPH Guru Trades in Q1 2015

Ken Fisher Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 29.79
XPH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 29.79 )
Ranked among companies with meaningful P/E(ttm) only.
XPH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 29.79
Current: 29.79
0
29.79
PE(NRI) 29.79
XPH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 29.79 )
Ranked among companies with meaningful PE(NRI) only.
XPH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 29.79
Current: 29.79
0
29.79
P/B 2.55
XPH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 2.55 )
Ranked among companies with meaningful P/B only.
XPH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 2.55
Current: 2.55
0
2.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.53
XPH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.53 )
Ranked among companies with meaningful Dividend Yield only.
XPH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.53
Current: 0.53
0
0.53
Yield on cost (5-Year) 0.53
XPH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.53 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XPH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.53
Current: 0.53
0
0.53

More Statistics

Short Percentage of Float0.00%
52-Week Range $37.82 - 114.28
Shares Outstanding (Mil)12,100,270.00
» More Articles for XPH

Headlines

Articles On GuruFocus.com
Timing and Legal Issues Thwart 2 Mergers Jul 28 2016 
A Cisco Dividend Play Is Not Just About Yield Jul 28 2016 
Microsoft, We Have a Surface Problem Jul 28 2016 
Should Johnson & Johnson Investors Be Worried About Ovarian Cancer Link? Jul 28 2016 
3 Pitfalls of Options Trading No One Mentions Jul 28 2016 
Harley Davidson: Wait for the Bear Market to Trade HOG Jul 28 2016 
Warren Buffett Is Wrong; Macro Is Important Part 2 Jul 28 2016 
Financial Tips Consumers Should Follow This Month Jul 28 2016 
Qualcomm or Advanced Micro Devices: Which Is the Better Bet? Jul 28 2016 
Apple's Earnings Signal New Direction for iPhone Maker Jul 28 2016 

More From Other Websites
What Key Developments Did JNJ Announce in 2Q16? Jul 26 2016
Expectations for Bristol-Myers Squibb’s 2Q16 Earnings Jul 25 2016
Inside Lilly’s 2Q16 Estimates for Its Cardiovascular Franchise Jul 22 2016
Best Sector ETFs for Q3 Jul 21 2016
Jazz Pharmaceuticals: How Much Return Potential Does It Have? Jul 15 2016
Check out Horizon’s Huge Upside Potential Jul 12 2016
What’s Really Driving Horizon’s Valuation? Jul 07 2016
Keytruda: Merck’s Immuno-Oncology Blockbuster Drug May 20 2016
Pharmaceuticals & Emerging Market: Two ETFs Trading with Outsized Volume May 20 2016
Januvia and Janumet: Merck’s Blockbuster Diabetes Drugs May 12 2016
Merck’s Valuation Cheat Sheet for Fiscal 1Q16 May 11 2016
Mudslinging Over Valeant Pharmaceuticals May 07 2016
How Eli Lilly’s Cardiovascular Franchise Performed in 1Q16 May 05 2016
Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus May 04 2016
Finding Pharmaceuticals ETFs With Rebound Potential May 04 2016
What Do Analysts Recommend for Jazz Pharmaceuticals? Apr 26 2016
Analyzing Akorn’s Strategy to Withstand Generic Industry Challenges Apr 20 2016
Is Mallinckrodt Spending Enough on R&D? Apr 11 2016
Your Horizon Breakdown: Performance across Segments Apr 06 2016
How Horizon Became a Growth Stock Mar 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK